Showing posts with label Cigna. Show all posts
Showing posts with label Cigna. Show all posts

Tuesday, March 31, 2015

Download the Updated 2015 MMCC Brochure

With an overflow of positive feedback about the program, we wanted to ensure everyone and everyone gets in on the action!

Download the brochure to view the full agenda for the Medicaid Managed Care Congress, taking place on May 20-22nd in Baltimore.

Highlights include:
• CMS Keynote speakers
• 20+ health plan case studies from Amerigroup, Molina Healthcare, Cigna-Health Spring and more!
• 15+ state government officials share unique programming
• NEW! An entire day focused on the opportunities of dual market
• And more!      

Register by Friday, April 24th and SAVE up to $200!
Use Priority Code: XP2026BLOG





Tuesday, June 10, 2014

AstraZeneca and Cigna in Evolutionary Partnership to Support Patients

Are you looking for an example of how data and technology are changing the healthcare delivery model? An innovative program announced June 2nd pairs Big Pharma with health insurer Cigna.

“Predictive Risk Modeling” is used to identify Cigna members who are most likely to benefit from treatment with the “aggressive LDL-C lowering” statin Crestor, a drug that is marketed by AstraZeneca.

When asked of the new partnership, Cigna said it is “the first of its kind” and represents a “targeted approach to helping high-risk patients with high cholesterol” receive value-based care.

Under the programs terms, Cigna said its member customers who are at increased risk for atherosclerotic cardiovascular disease – ASCVD – and need to aggressively manage their LDL cholesterol can be prescribed and receive Crestor “without requiring prior authorization.”

In a statement, Cigna said “As an integrated health services company, Cigna is able to use both medical and pharmacy information in predictive risk modeling to appropriately assess a customer’s overall health condition, this approach analyzes multiple clinical factors to identify customers most at risk for ASCVD related to high cholesterol. When a doctor prescribes CRESTOR, customers identified as being at higher risk will no longer be subject to “step therapy” – where a generic alternative is tried first…”

Philip de Vane, MD, AstraZeneca’s executive director of U.S. medical affairs, said this new arrangement represents “an evolutionary step in supporting patient health, and facilitating access to Crestor for high risk patients. Predictive risk modeling can be used to help support the right treatment for the right patient at the right time, and we are excited to be working with Cigna because they are the only insurance carrier or Pharmacy Benefit Manager (PBM) we have seen who has offered this capability.”

This new partnership is certainly worth watching, and is another example of how new thinking is creating new opportunities across the patient-pharma-payer spectrum.

Read the full Cigna news release here.

As an industry professional, do you expect more partnerships like this one to pop up? Or is this partnership model going to struggle for greater adoption?





Monday, July 12, 2010

Value Driven Pharma - 2010 Brochure Ready for Download

IIR’s 2nd Annual Value-Driven Pharma is not just another managed market event – it delves deeper than ever before to give you the tools to reconcile government, payer and patient perspectives on drug valuation to bring you closer to the patients you serve.
Explore risk-sharing contracts like CIGNA & Merck and Health Alliance & P&G, to evaluate the demand for more outcomes data from payers and the requirements around Comparative Effectiveness Research to pave the way for formulary placement from the earliest point possible in the development cycle.

Download the brochure to find out more about the speakers and presentations at this year's event:



Key Takeaways for 2010:
• Benefit from over 20 hours of face-to-face working groups, networking breaks, and roundtable luncheons.
• Tackle challenges that come with payers increased focus on innovation that supports better health and financial outcomes for patients
• Improve the relationship and communication between manufacturers and payers to align all the incentives behind improving patient value.
• Learn how to break free from organizational silos, to leverage CER data to craft a successful value proposition, and use risk-sharing contracting to ensure market access.